Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Conestat alfa - Pharming Group

Drug Profile

Conestat alfa - Pharming Group

Alternative Names: Human C1 esterase inhibitor - Pharming; Recombinant human C1 esterase inhibitor - Pharming; rhC1INH; Rhucin; Ruconest

Latest Information Update: 28 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharming Group NV
  • Class Anti-inflammatories; Antihypertensives; Complement C1 inactivator proteins; Recombinant proteins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Delayed graft function; Capillary leak syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase II COVID 2019 infections; Stroke
  • No development reported Delayed graft function; Shock
  • Discontinued Acute kidney injury; Preeclampsia; Renal transplant rejection

Most Recent Events

  • 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in Switzerland (IV, Infusion)
  • 04 Aug 2022 Discontinued - Phase-I/II for Preeclampsia (Prevention) in Australia (unspecified route) as per company decision
  • 04 Aug 2022 Discontinued - Phase-I/II for Preeclampsia (Prevention) in Netherlands (unspecified route) as per company decision
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top